ArticleFrontiers in oncology2024

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Christopher Hackenbruch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.